Haemodialysis and Vascular Access in the End Stage Kidney Disease
European Journal of Clinical and Biomedical Sciences
Volume 3, Issue 1, February 2017, Pages: 1-6
Received: Nov. 16, 2016; Accepted: Dec. 22, 2016; Published: Jan. 12, 2017
Views 2803      Downloads 83
Authors
Muhammad A. Siddiqui, School of Health Sciences, Queen Margaret University, Edinburgh, UK
Derek Santos, School of Health Sciences, Queen Margaret University, Edinburgh, UK
Suhel Ashraff, School of Health Sciences, Queen Margaret University, Edinburgh, UK; Department of Medicine, Royal Victoria Infirmary, Newcastle, UK
Thomas Carline, School of Health Sciences, Queen Margaret University, Edinburgh, UK
Article Tools
Follow on us
Abstract
The efficiency of haemodialysis treatment relies on a functional status of vascular access. A vascular access makes life-saving haemodialysis treatments possible. The efficiency of haemodialysis treatment relies on a functional status of vascular access. The purpose of this review was to discuss the role of haemodialysis and vascular access in end stage kidney disease. Vascular access and its related problems represent the main factors that determine a rise in the rate of incidence of the disease among haemodialysis patients and, consequently, a rise in the healthcare expenses. Vascular access can be divided into three categories: arteriovenous fistula, central venous catheter and arteriovenous graft. Central venous catheter has a number of disadvantages, including a considerable risk of infection and mortality. It also has negative implications for the use of a fistula for dialysis. In contrast, arteriovenous fistula is the most beneficial method, as it has a low risk of infection and mortality, and can ensure long-term functional access. Furthermore, there are three configurations of native arteriovenous fistula that can be used for haemodialysis providing flexibility of approach depending on risk factors of the individual patient.
Keywords
Haemodialysis, Vascular Access, End Stage Kidney Disease
To cite this article
Muhammad A. Siddiqui, Derek Santos, Suhel Ashraff, Thomas Carline, Haemodialysis and Vascular Access in the End Stage Kidney Disease, European Journal of Clinical and Biomedical Sciences. Vol. 3, No. 1, 2017, pp. 1-6. doi: 10.11648/j.ejcbs.20170301.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
National Institute for Health and Care Excellence. 2014. Chronic kidney disease in adults: assessment and management (CG 182). [Online]. Available at < https://www.nice.org.uk/guidance/cg182 > [Accessed Oct 2016].
[2]
UK Renal Registry Report. 2011. UK Renal Registry 14th Annual Report: Chapter 2.
[3]
Grassmann, A., Gioberge, S., Moeller, S. and Brown, G. 2006. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs, 30, pp. 895–897.
[4]
Paskalev, D. N. 2001. Georg Haas (1886–1971): The Forgotten Haemodialysis Pioneer. Dial Transplant, 30 (12), pp. 828-832.
[5]
Kolff, W. J., and Berk, H. T. J. 1944. Artificial kidney: a dialyser with great area. Acta Med Scand, 117, pp. 121-134. [Online]. Available at < http://jasn.asnjournals.org/content/8/12/1959.full.pdf+html > [Accessed June 2016].
[6]
Konner, K. 2005. History of vascular access for haemodialysis. Nephrol Dial Transplant, 20, pp. 2629-2635.
[7]
Manns, B., Tonelli, M., Yilmaz, S., Lee, H., Laupland, K., Klarenbach, S., Radkevich, V. and Murphy, B. 2005. Establishment and maintenance of vascular access in incident haemodialysis patients: A prospective cost analysis. J Am Soc Nephrol, 16, pp. 201–209.
[8]
Anel, R. L., Yevzlin, A. S. and Ivanovich, P. 2003. Vascular access and patient outcomes in haemodialysis: questions answered in recent literature. Art if Organs, 27, p. 237.
[9]
Pandya, P. and Farrington, K. 2003. Haemodialysis. Chronic Renal Failure, pp. 66-69.
[10]
NKF-KDOQI. 2006. Clinical practice guidelines for haemodialysis adequacy updated. [Online]. Available at http://www.kidney.org/professionals/kdoqi/guideline_uphd_pd_va/index.htm > [Accessed Aug 2016].
[11]
Avram, M. M., Mittman, N., Bonomini, L., Chattopadhyay, J. and Fein, P. 1995. Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis, 26, pp. 209-219.
[12]
Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. and Port, F. K. 1998. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients: a national study. Am J Kidney Dis, 31, pp. 607-617.
[13]
Locatelli, F., Pisoni, R. L., Akizawa, T., Cruz, J. M., DeOreo, P. B., Lameire, N. H. and Held, P. J. 2004. Anaemia management for haemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis, 44, pp. 27-33.
[14]
Held, P. J., Port, F. K., Wolfe, R. A., Stannard, D. C., Carroll, C. E., Daugirdas, J. T., Bloembergen, W. E., Greer, J. W. and Hakim, R. M. 1996. The dose of haemodialysis and patient mortality. Kidney Int, 50, pp. 550-556.
[15]
Elseviers, M. M. and Van Waeleghem, J. P. 2003. Identifying vascular access complications among ESRD patients in Europe. A prospective, multicentre study. Nephrol News Issues, 17, pp. 61-68.
[16]
NKF-KDOQIa. 2006. Clinical practice guidelines for vascular access. Am J Kidney Dis, 48 (Suppl 1), pp. S248–S272.
[17]
Rayner, H. C., Pisoni, R. L., Gillespie, B. W., Goodkin, D. A., Akiba, T., Akizawa, T., Saito, A., Young, E. W. and Port, F. K. 2003. Creation, cannulation and survival of arteriovenous fistulae: Data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int, 63, pp. 323–330.
[18]
USRDS (US Renal Data System). 2011. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
[19]
Alwall, N., Bergsten, B. W. B., Gedda, P. O., Norviit, L. and Steins, A. M. 1949. On the Artificial Kidney IV. Acta Medica Scandinavica, 0XXXII. [Online]. Available at < http://onlinelibrary.wiley.com/doi/10.1111/j.0954-6820.1949.tb18183.x/abstract > [Accessed July 2016].
[20]
Quinton, W. E., Dillard, D. H. and Scribner, B. H. 1960. Cannulation of blood vessels for prolonged haemodialysis. Trans Am Soc Artif Intern Organs, 6, pp. 511- 519.
[21]
Brescia, M. J., Cimino, J. E., Appel, K., Hurwich, B. J. 1966. Chronic haemodialysis using venepuncture and a surgically created arteriovenous fistula. N Engl J Med, 275, pp. 1089–1092.
[22]
Sperling, M., Kleinschmidt, W., Wilhelm, A., Heidland, A. and Klutsch, K. 1967. Die subkutane arteriovenose Fistel zur intermittierenden Hamodialyse-Behandlung. Dtsch Med Wschr, 92, pp. 425-426.
[23]
Fluck, R., Rao, R., Schalkwyk, D., Ansell, D. and Feest, T. 2007. The UK Vascular Access Survey – Follow up data and repeat survey (Chapter 5). Nephrol Dial Transplant, 22 (S7), pp. 51-57.
[24]
Thomas, G. I. 1969. A large vessel appliqué AV shunt for haemodialysis. Trans Am Soc Artif Intern Organs, 15, pp. 288-92.
[25]
Higgs, Z. C., Macafee, D. A., Braithwaite, B. D. and Maxwell-Armstrong, C. A. 2005. The Seldinger technique: 50 years on. Lancet, 366, pp. 1407-1409.
[26]
Shaldon, S. 1994. Percutaneous vessel catheterization for haemodialysis. ASAIO J, 40, pp. 17-19.
[27]
Schillinger, F., Schillinger, D., Montagnac, R. and Milcent, T. 1991. Post catheterization vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant, 6, pp. 722-724.
[28]
Bourquelot, P. 2009. Vascular access for haemodialysis. Nephrol Ther, 5 (3), pp. 239- 438.
[29]
Banerjee, S. 2009. Dialysis Catheters and Their Common Complications: An Update. Scientific World Journal, 9, pp. 1294–1299.
[30]
Asif, A. 2008. Reducing the morbidity of tunneled haemodialysis catheters—a symposium. Semin. Dial. 21 (6), p. 503.
[31]
Feldman, H. I., Kobrin, S. and Wasserstein, A. 1996. Haemodialysis vascular access morbidity. J Am Soc Nephrol, 7, pp. 523–535.
[32]
Windus D. W. 1993. Permanent vascular access: Anephrologist’s view. Am J Kidney Dis 21, pp. 457–451.
[33]
Bender, M. H. M., Bruyninckx, M. A., Gerlag, P. G. G. 1994. The brachiocephalic elbow fistula: A useful alternative angioaccess for permanent haemodialysis. J Vasc Surg, 20, pp. 808–813.
[34]
Coburn, M. C. and Carney, W. I. 1994. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc Surg, 20, pp. 896–904.
[35]
Parienti, J., Dugue, A. E., Daurel, C., Mira, J., Megarbane, B., Mermel, L. A., Daubin, C. and Cheyron, D. 2010. Continuous Renal Replacement Therapy May Increase the Risk of Catheter Infection. Clin J Am Soc Nephrol, 5 (8), pp. 1489–1496.
[36]
Hannah, E. L., Stevenson, K. B., Lowder, C. A., Adcox, M. J., Davidson, R. L., Mallea, M. C., Narasimhan, N. and Wagnild, J. P. 2002. Outbreak of haemodialysis vascular access site infections related to malfunctioning permanent tunnelled catheters: making the case for active infection surveillance. Infect. Control Hosp. Epidemiol. 23, pp. 538-541.
[37]
Beathard, G. A. and Urbanes, A. 2008. Infection associated with tunnelled haemodialysis catheters. Semin. Dial, 21 (6), pp. 528–538.
[38]
Bittl JA. 2010. Catheter interventions for haemodialysis fistulas and grafts. JACC Cardiovasc Interv. 3 (1), pp. 1-11.
[39]
Roy-Chaudhury, P., Kelly, B. S. and Miller, M. A. 2001. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int, 59, pp. 2325-2334.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186